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Summary
Background: JM216 is a new oral platinum complex with dose-
limiting toxicity myelosuppresssion, now undergoing phase II
evaluation.
Patients and methods: JM216 was evaluated as first line
therapy in non-small-cell lung cancer. Seventeen patients re-
ceived 120 mg/nr/day for five days repeated every three weeks.
Results: Toxicity was manageable, the commonest side-
effects being nausea, vomiting, diarrhoea, constipation and
asthenia. Myelososuppression was generally grade < 2 and
there were no cases of neutropenic sepsis or bleeding. Thirteen
patients were fully evaluable for response. No sustained objec-
tive responses were reported. One patient was reported as
stable disease had a partial response after three courses but
was progressing again after four. An additional five patients
had stable disease (46.2%).
Conclusions: Although some patients may have had useful
palliation, JM216 did not appear to have significant antitu-
mour activity in non-small-cell lung cancer.
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Introduction
Lung cancer is one of the leading causes of death in men
and women [1]. Non-small-cell lung cancer usually
presents as a systemic disease for which palliative treat-
ment only is available. Single agent chemotherapy has
been studied extensively in this disease, with cisplatin
producing the most consistent response rates in the
region of 20% [2]. An oral platinum agent with mild
toxicity would be of value in this setting.
The ammine/amine platinum (IV) dicarboxylates [3]
were developed with the intention that their enhanced
lipophilicity and stability would both improve drug ab-
sorption and reduce local toxicity within the gut com-
pared with cisplatin and carboplatin. Bis(acetatato) am-
mine cyclohexylamine dichloro platinum (IV), or JM216,
was chosen for clinical development due to superior oral
activity in vivo compared with cisplatin, carboplatin and
tetraplatin [4], and a favourable toxicity profile with
dose-limiting myelosuppression [5, 6].
In a phase I study of JM216 using a single oral dose
daily x 5 every three to four weeks, the maximum
tolerated dose was 140 mg/m2/day. The dose-limiting
toxicity was myelosuppression, non-haematological tox-
icities were mild and some evidence of antitumour activ-
ity was observed [7]. Starting doses of 100 mg/m2/
day x 5 for previously treated patients and 120 mg/m2/
day x 5 for previously untreated patients were recom-
mended for phase II evaluation using this schedule. This
phase II study was conducted in previously untreated
patients with locally advanced, unresectable or meta-
static non-small-cell lung cancer.
Patients and methods
Eligibility
Inclusion criteria were histologically or cytologically verified non-
small-cell lung cancer >1 , bidimensionally measurable lesion, WHO
performance status (PS) ^ 2 , age >18 years, adequate bone marrow
function, creatinine < 140 (imol/1 and if > 100 nmol/1 a creatinine
clearance >60 ml/min, bilirubin <26 |imol/l and transaminases
<2x upper limit of normal unless due to known liver metastases.
Exclusions were prior chemotherapy, radiotherapy < 4 weeks previ-
ously or to the indicator lesion, and brain or meningeal disease. All
patients were required to give informed consent according to local
ethical committee guidelines.
Pharmaceutical and treatment information
JM216 was provided by Bristol-Myers Squibb as 10 mg, 50 mg and
200 mg capsules and given at a starting dose of 120 mg/m2/day x 5
every three weeks or upon bone marrow recovery, i.e. WBC
> 3.5 x 109/l, neutrophils > 1.5 x 1O9/1, platelets > 100 x io'/l. Treat-
ment could be delayed in the case of renal to.xicity grade > 1, neuro-
toxicity grade > 1 and any other unresolved toxicity apart from alopecia
Dose modifications were: dose reduction to 100 mg/nr/day for grade 4
neutropenia or thrombocytopenia, grade 2 neurotoxicity, or other
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grade 3 non-haematological toxicity apart from gastrointestinal or
alopecia, withdrawal for grade > 2 nephrotoxicity, grade > 3 neuro-
toxicity, grade 4 other toxicity; dose increase to 140 mg/m2/day x5 m
the absence of grade 2 haematological toxicity at nadir or other
significant toxicities. Patients were considered evaluable for response
after two cycles, progression after one cycle designating early progres-
sion. Concurrent radiotherapy for pain outside the indicator lesion(s)
was permitted. The choice of antiemetic treatment was not specified
and a variety of different regimens were used.
Toxicity and response evaluation
Toxicities were graded according to NCI Common Toxicity Critena
and serious adverse events were reported immediately to the Study
Coordinator. Tumour evaluation was performed prior to and after every
two cycles of treatment. Physical examination and assessment of perfor-
mance status were performed every three weeks, plasma biochemistry
every three weeks and full blood count weekly. Responses were eval-
uated according to standard WHO criteria.
Results
Patients and treatment
Eighteen patients were registered, 13 male, 5 female,
with a mean age of 61 years (range 45-79), 12 patients
were PS 1 and 6 PS 2. Five patients had prior surgery,
three prior radiotherapy, and none prior systemic treat-
ment. Nine patients had metastatic disease other than
hilar lymphadenopathy at the time of treatment, an addi-
tional three patients had disease in mediastinal nodes.
One patient received no treatment, three received in-
complete treatment during the cycle two and one re-
ceived 1/5 the appropriate dose in error. A total of 38
courses were administered, four patients received ^ 1
dose reductions, in two due to myelosuppression, in one
due to grade 3 diarrhoea, and in one due to a prescribing
error. In four patients the dose was increased to 140 mg/
m2/day. Treatment delay occurred in 11 patients with
delays from 1-14 days (median seven days) in six pa-
tients due to myelosuppression, in five unrelated to treat-
ment. Twelve patients had ^ 2 courses, two patients
received five courses.
Toxicity
Principal non-haematological toxicities were nausea and
vomiting, diarrhoea, constipation and asthenia. Gastro-
intestinal toxicity is given in Table 1. Only 10 patients
Table 1. Incidence of gastrointestinal toxicity in 17 patients receiving
JM216 as defined by worst CTC grade per patient.






























(55%) received a 5HT3 antagonist with their first course
of JM216, two additional patients received one subse-
quently. The remaining patients received dopamine an-
tagonists and steroids only. Three patients reported
grade 3 asthenia which was possibly drug related. One
patient had grade 3 focal motor neurological toxicity,
probably related to occult disease progression. All other
non-haematological toxicities were grade ^ 2.
Haematological toxicity was easily manageable. Anae-
mia was usually grade ^ 1 and never > 2. Most courses
(28 of 38) were associated with grade ^ 1 thrombocyto-
penia but there were three cases of grade 3 thrombocy-
topenia and three of grade 4. The median platelet nadir
fell from 123 x 109/l after course 1 to 54 x 109/l after
course 5, but few patients received > 2 courses making
it difficult to draw conclusions from this observation.
The majority of patients had no significant leukopenia
which was grade < 1 in 32 of 38 courses. Only one patient
had grade 3 leukopenia and two grade 3 neutropenia.
There were no cases of serious drug-related sepsis.
Most serious adverse events were due to disease pro-
gression. Treatment was stopped due to toxicity in three
patients, in each case because of myelosuppression, in
two cases prolonged leukopenia and thrombocytopenia,
in one case grade 4 thrombocytopenia.
Response
Only 13 patients were fully evaluable for response. Rea-
sons for exclusion were early death in one patient, treat-
ment discontinuation in one following myocardial in-
farction after two cycles, follow-up evaluation either not
done or performed at the wrong time in two and failure
to receive treatment in one. There were no sustained
objective responses to JM216. One patient had a partial
response in the primary tumour after three cycles, as
measured by CT scan, but was progressing again after
four cycles. The tumour remained smaller than at the
start of treatment and the patient was recorded as stable
disease. An additional five patients were reported as no
change. Four patients continued treatment after two
cycles due to stable disease or symptomatic benefit.
There were seven cases of progressive disease, four of
them early.
Discussion
The oral platinum complex JM216 was well tolerated in
this group of patients with non-small-cell lung cancer.
Subjective toxicities were generally ^ grade 2 although
nausea, vomiting, diarrhoea and asthenia could be more
severe. Haematological toxicity was surprisingly low
with almost no grade >2 leukopenia or neutropenia.
Neutropenic sepsis was not observed. Thrombocytope-
nia was more frequent but was grade ^ 2 following 84%
of courses administered. There were no problems with
bleeding related to thrombocytopenia. Four patients
(23% of patients treated) had their dose increased from
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120 to 140 mg/m2/day. Treatment delay occurred in six
patients due to delayed haematological recovery and
therefore it may be more appropriate for treatment to
be repeated every four weeks rather than every three as
intended in this study.
The lack of objective antitumour activity was disap-
pointing with no sustained objective responses with 13
patients evaluable for response. Nevertheless, of these
patients six had stable disease (46.2%) and there was
some evidence of disease palliation. In studies with
single agent cisplatin, response rates were in the order
of 20% [2] and there was also said to be a dose-response
relationship. Carboplatin may be somewhat less active,
with an overall response rate in the region of 12% [8]. It
must be acknowledged that JM216 as a single agent
given according to this dose and schedule is inactive in
non-small-cell lung cancer but randomised studies would
be required to define properly its role in combination
with agents of proven activity.
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